A microfluidic diagnostic chip may comprise a microfluidic channel, a functionalizable enzymatic sensor in the microfluidic channel, the functionalizable enzymatic sensor comprising a binding surface to bind with a biomarker in a fluid, and a microfluidic pump to pass the fluid over the binding surface. A microfluidic device may comprise a number of pumps to pump a fluid though the number of microfluidic channels and a number of microfluidic channels comprising at least one sensor to detect a change in a chemical characteristic of the fluid in response to presence of the fluid on the sensor

A microfluidic diagnostic chip may comprise a microfluidic channel, a functionalizable enzymatic sensor in the microfluidic channel, the functionalizable enzymatic sensor comprising a binding surface to bind with a biomarker in a fluid, and a microfluidic pump to pass the fluid over the binding surface. A microfluidic device may comprise a number of pumps to pump a fluid though the number of microfluidic channels and a number of microfluidic channels comprising at least one sensor to detect a change in a chemical characteristic of the fluid in response to presence of the fluid on the sensor

Embodiments disclosed herein provide methods for identifying cell-type-specific nucleosomal DNA modifications. The methods leverage nucleosomal DNA barcoding and pool-and-split multiplexing to provide high-throughout, quantitative profiling of nucleosomal DNA states. The methods enable the profiling of multiple nucleosomal DNA marks across different cell types and/or conditions thereby linking quantitative changes in chromatin landscapes to different genotypes and chemical and physical perturbations

Embodiments disclosed herein provide methods for identifying cell-type-specific nucleosomal DNA modifications. The methods leverage nucleosomal DNA barcoding and pool-and-split multiplexing to provide high-throughout, quantitative profiling of nucleosomal DNA states. The methods enable the profiling of multiple nucleosomal DNA marks across different cell types and/or conditions thereby linking quantitative changes in chromatin landscapes to different genotypes and chemical and physical perturbations

This invention provides methods for characterizing the amounts of nucleic acids, including plus/minus determinations, the use of different constructs, the use of a library and a reference library. Expression may also be compared in two or more samples using the methods of this invention. Also provided are heterophasic arrays comprising labeled positive copies of nucleic acids hybridized to the array and labeled negative copies of nucleic acids hybridized to the array, in which the labeled positive copies are separately quantifiable from the labeled negative copies.

This invention provides methods for characterizing the amounts of nucleic acids, including plus/minus determinations, the use of different constructs, the use of a library and a reference library. Expression may also be compared in two or more samples using the methods of this invention. Also provided are heterophasic arrays comprising labeled positive copies of nucleic acids hybridized to the array and labeled negative copies of nucleic acids hybridized to the array, in which the labeled positive copies are separately quantifiable from the labeled negative copies.

The present invention relates to the amplification and/or detection of nucleic acid molecules. More specifically, the present invention relates to the sensitive amplification, detection, and/or quantification of nucleic acid molecules.

The present invention relates to the amplification and/or detection of nucleic acid molecules. More specifically, the present invention relates to the sensitive amplification, detection, and/or quantification of nucleic acid molecules.

The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly mRNA synthesized in vitro. In some embodiments, methods according to the present invention comprise providing an mRNA sample containing capped and uncapped mRNA, providing a cap specific binding substance under conditions that permit the formation of a complex between the cap specific binding substance and the capped mRNA, and quantitatively determining the amount of the complex as compared to a control, thereby quantifying mRNA capping efficiency.

The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly mRNA synthesized in vitro. In some embodiments, methods according to the present invention comprise providing an mRNA sample containing capped and uncapped mRNA, providing a cap specific binding substance under conditions that permit the formation of a complex between the cap specific binding substance and the capped mRNA, and quantitatively determining the amount of the complex as compared to a control, thereby quantifying mRNA capping efficiency.